Aligos Therapeutics, Inc. Diluted Shares Outstanding (Weighted Average)
Aligos Therapeutics, Inc. (ALGS) reported Diluted Shares Outstanding (Weighted Average) of 10.43 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-06
- Aligos Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 10.43M shares, a 0.77% increase year-over-year.
- Aligos Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 10.40M shares, a 19.44% increase year-over-year.
- Aligos Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 10.39M shares, a 65.37% increase year-over-year.
- Aligos Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 10.37M shares, a 65.32% increase year-over-year.
- Aligos Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 9.88M shares, a 57.79% increase from fiscal 2024.
- Aligos Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 6.26M shares, a 144.38% increase from fiscal 2023.
- Aligos Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 2.56M shares, a 94.00% decline from fiscal 2022.
- Aligos Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2022 was 42.70M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 12 month | Weighted Average Number of Shares Outstanding, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 10.43M shares 10-Q · filed 2026-08-06 | 10.42M shares 10-Q · filed 2026-08-06 | 10.41M shares derived: average of 3 quarters · filed 2026-08-06 | 10.40M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | 10.40M shares 10-Q · filed 2026-05-07 | 10.40M shares derived: average of 2 quarters · filed 2026-05-07 | 10.39M shares derived: average of 3 quarters · filed 2026-05-07 | 10.38M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | 10.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 10.38M shares derived: average of 2 quarters · filed 2026-03-05 | 10.37M shares derived: average of 3 quarters · filed 2026-08-06 | 9.88M shares 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | 10.37M shares 10-Q · filed 2025-11-06 | 10.36M shares derived: average of 2 quarters · filed 2026-08-06 | 9.72M shares 10-Q · filed 2025-11-06 | 8.93M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | 10.35M shares 10-Q · filed 2026-08-06 | 9.40M shares 10-Q · filed 2026-08-06 | 8.45M shares derived: average of 3 quarters · filed 2026-08-06 | 7.90M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | 8.71M shares 10-Q · filed 2026-05-07 | 7.50M shares derived: average of 2 quarters · filed 2026-05-07 | 7.09M shares derived: average of 3 quarters · filed 2026-05-07 | 6.88M shares derived: average of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | 6.28M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 6.28M shares derived: average of 2 quarters · filed 2026-03-05 | 6.27M shares derived: average of 3 quarters · filed 2026-03-05 | 6.26M shares 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | 6.27M shares 10-Q · filed 2025-11-06 | 6.27M shares derived: average of 2 quarters · filed 2025-11-06 | 6.26M shares 10-Q · filed 2025-11-06 | 5.96M shares derived: average of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | 6.27M shares 10-Q · filed 2025-08-06 | 156.65M shares 10-Q · filed 2024-08-06 | 6.25M shares 10-Q · filed 2025-08-06 | 156.30M shares 10-Q · filed 2024-08-06 | 5.86M shares derived: average of 3 quarters · filed 2025-08-06 | 4.83M shares derived: average of 4 quarters · filed 2025-08-06 | ||
| 2024-03-31 | 6.25M shares 10-Q · filed 2025-05-06 | 156.15M shares 10-Q · filed 2024-05-07 | 5.66M shares derived: average of 2 quarters · filed 2025-05-06 | 4.35M shares derived: average of 3 quarters · filed 2025-05-06 | 14.07M shares derived: average of 4 quarters · filed 2025-05-06 | |||
| 2023-12-31 | 5.07M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 3.40M shares derived: average of 2 quarters · filed 2025-03-10 | 16.67M shares derived: average of 3 quarters · filed 2025-03-10 | 2.56M shares 10-K · filed 2025-03-10 | 64.26M shares 10-K · filed 2024-03-12 | |||
| 2023-09-30 | 1.74M shares 10-Q · filed 2024-11-06 | 43.50M shares 10-Q · filed 2023-11-02 | 22.48M shares derived: average of 2 quarters · filed 2024-11-06 | 1.73M shares 10-Q · filed 2024-11-06 | 43.21M shares 10-Q · filed 2023-11-02 | 32.68M shares derived: average of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | 43.22M shares 10-Q · filed 2024-08-06 | 43.06M shares 10-Q · filed 2024-08-06 | 42.99M shares derived: average of 3 quarters · filed 2024-08-06 | 42.93M shares derived: average of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | 42.91M shares 10-Q · filed 2024-05-07 | 42.87M shares derived: average of 2 quarters · filed 2024-05-07 | 42.84M shares derived: average of 3 quarters · filed 2024-05-07 | 42.79M shares derived: average of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | 42.84M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | 42.80M shares derived: average of 2 quarters · filed 2024-03-12 | 42.76M shares derived: average of 3 quarters · filed 2024-03-12 | 42.70M shares 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | 42.76M shares 10-Q · filed 2023-11-02 | 42.71M shares derived: average of 2 quarters · filed 2023-11-02 | 42.65M shares 10-Q · filed 2023-11-02 | |||||
| 2022-06-30 | 42.67M shares 10-Q · filed 2023-08-03 | 42.59M shares 10-Q · filed 2023-08-03 | ||||||
| 2022-03-31 | 42.51M shares 10-Q · filed 2023-05-04 | |||||||
| 2021-09-30 | 42.40M shares 10-Q · filed 2022-11-02 | 39.15M shares 10-Q · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |